⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
POLYMED - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.6
| Stock Code | POLYMED | Market Cap | 12,985 Cr. | Current Price | 1,281 ₹ | High / Low | 2,938 ₹ |
| Stock P/E | 37.4 | Book Value | 285 ₹ | Dividend Yield | 0.27 % | ROCE | 18.2 % |
| ROE | 14.2 % | Face Value | 5.00 ₹ | DMA 50 | 1,437 ₹ | DMA 200 | 1,793 ₹ |
| Chg in FII Hold | -0.36 % | Chg in DII Hold | 0.31 % | PAT Qtr | 83.4 Cr. | PAT Prev Qtr | 89.0 Cr. |
| RSI | 42.7 | MACD | -46.0 | Volume | 1,71,071 | Avg Vol 1Wk | 1,52,734 |
| Low price | 1,210 ₹ | High price | 2,938 ₹ | PEG Ratio | 1.21 | Debt to equity | 0.08 |
| 52w Index | 4.09 % | Qtr Profit Var | -2.04 % | EPS | 33.8 ₹ | Industry PE | 33.9 |
📊 Technical Analysis
- Chart Patterns: Stock is trading below both 50-DMA (₹1,437) and 200-DMA (₹1,793), showing weakness and continuation of downtrend.
- Moving Averages: Current price ₹1,281 is under both DMAs, confirming bearish bias.
- RSI: 42.7 — neutral zone, leaning toward weakness.
- MACD: -46.0 — bearish crossover, momentum weak.
- Bollinger Bands: Price near lower band, suggesting possible mean reversion.
- Volume Trends: Current volume (1.71L) slightly above 1-week average (1.52L), showing active trading but not strong buying interest.
📈 Momentum & Signals
- Short-term Momentum: Weak, consolidation with bearish undertone.
- Entry Zone: ₹1,210–₹1,281 (support levels).
- Exit Zone: ₹1,437–₹1,793 (resistance levels).
- Trend Status: Stock is consolidating with bearish bias.
✅ Positive
- PEG ratio of 1.21 suggests fair valuation relative to growth.
- Low debt-to-equity (0.08), financially stable.
- Strong book value (₹285) compared to current price, offering cushion.
⚠️ Limitation
- High P/E (37.4) compared to industry average (33.9), slightly overvalued.
- Quarterly PAT declined (₹83.4 Cr vs ₹89 Cr).
- Weak ROCE (18.2%) and ROE (14.2%), showing moderate efficiency.
📰 Company Negative News
- Quarterly profit variance -2.04% shows earnings pressure.
- FII holdings decreased (-0.36%), showing reduced foreign investor confidence.
🌟 Company Positive News
- DII holdings increased (+0.31%), showing domestic institutional support.
- EPS of ₹33.8 provides a stable earnings base.
🏭 Industry
- Industry P/E at 33.9, slightly lower than company’s P/E (37.4), suggesting sector peers may be more attractively priced.
- Medical devices sector remains resilient with long-term demand outlook.
🔎 Conclusion
- Stock is consolidating near support with weak momentum.
- Short-term traders may consider entry near ₹1,210–₹1,281 with exit around ₹1,437–₹1,793.
- Medium-term investors should be cautious due to weak efficiency metrics despite fair valuation.